China: Healthcare

Subscribe

Welcome to the Mondaq Food, Drugs, Healthcare, Life Sciences homepage, here you will find thought leadership articles, podcasts, videos and webinars providing insights covering topics such as Food and Drugs Law, Healthcare, Life Sciences, Biotechnology and Nanotechnology.

What Are The Contract Essentials For China-related Life Sciences Collaboration Agreements?

China is becoming an increasing focus for transactions in the pharmaceuticals sector with its growing investment into research and development, government support and a steady...

Worldwide Healthcare

GW

Gowling WLG

Industry Observation｜China Life Sciences And Healthcare Weekly Report No. 30

为进一步完善全链条支持创新药发展举措，推动创新药高质量发展，更好满足人民群众多元化就医用药需求，国家医保局、国家卫生健康委联

China Healthcare

SG

SGLA Law Firm

China On The Move: China's Healthcare And Life Sciences Regulatory Evolution In 2025

In the first half of 2025, China's healthcare and life sciences regulatory framework underwent a wave of important reforms. These developments reflect the country's continued efforts toward global alignment...

China Healthcare

GT

Greenberg Traurig, LLP

China Compliance Update – Summer 2025

Anti-corruption has remained an area of focus area for Chinese authorities in the first half of 2025, with major legislative updates and enforcement cases.

AP

Arnold & Porter

The Regulatory Data Protection Regime In China (Draft For Comments)

China Healthcare

FP

Fangda Partners

China Compliance Update: Life Sciences — Summer 2025

China Healthcare

AP

Arnold & Porter

Growth and Opportunities in China's Medical Device Market.

China Healthcare

A

Acclime

中国创新药械全球崛起法律保障系列文章之一：创新药研发企业临床试验数据对外跨境传输的监管要点

AB

AnJie Broad Law Firm

试管婴儿辅助生殖行业法律问题探究

China Healthcare

AB

AnJie Broad Law Firm

China Advances Pharmaceutical Data Protection Regime With New Draft Measures

China Healthcare

AO

A&O Shearman

里程碑式判决：经营者集中行政诉讼"第一案"代理有感

China Anti-trust

AB

AnJie Broad Law Firm

Safeguards Of Dapagliflozin's Half Billion USD Sales In China: AstraZeneca

R

Rouse

China Newsletter | Q4 2024/Issue No. 62

China International

GT

Greenberg Traurig, LLP

China Unveils New Anti-Monopoly Guidelines For The Pharmaceutical Sector

China Anti-trust

JD

Jones Day

《上市公司重大资产重组管理办法》新法修订要点解析与实务影响

China Commercial

AB

AnJie Broad Law Firm

PRC Financial Regulation: Annual Report (2024) FinTech

China Technology

FP

Fangda Partners

DeepSeek Facing Legal Challenges In Overseas Market

Worldwide Technology

LO

Llinks Law Offices

PRC Financial Regulation: Annual Report (2024) - Banking

FP

Fangda Partners

试管婴儿辅助生殖行业法律问题探究

China Healthcare

AB

AnJie Broad Law Firm

China Life Sciences: 2024 Year In Review

The life sciences industry remained a primary focus for Chinese regulators in 2024. Key developments such as China's first draft law regulating the medical device industry, the Medical Device Administration Law (《中华人民共和国医疗器械管理法（草案征求意见稿）》),

China Healthcare

AP

Arnold & Porter

China Tightens The Reins: Anti-Corruption Compliance Expectations For Companies In The Healthcare Sector

This month, as part of China's ongoing anti-corruption campaign in the healthcare sector, the State Administration for Market Regulation (SAMR) issued the Compliance Guidelines...

RG

Ropes & Gray LLP

Chinese Regulators Publish Final Anti-Corruption Guidelines For The Healthcare Industry

On January 14, 2025, the State Administration for Market Regulation (SAMR, 国家市场监督管理总局) published the Compliance Guidelines for Healthcare Companies to Prevent Commercial Bribery Risks...

China Healthcare

AP

Arnold & Porter

China Announces Major Policy Incentives For Life Sciences Companies

On December 30, 2024, China's State Council published a series of policy incentives in Circular No. 53 to stimulate the transformation of the country's life sciences industry.

China Healthcare

RG

Ropes & Gray LLP

China's New Draft Administrative Measures For Management Of Medical Representatives

China Healthcare

AP

Arnold & Porter

The New Draft Administrative Measures For Management Of Medical Representatives

China Healthcare

AP

Arnold & Porter

中国在医疗和生物技术领域的外资新政策：推动创新发展与加强专利保护

China Healthcare

L

Lusheng Law Firm

Relaxation Of Long-Standing Restrictions On Foreign Investment In The Healthcare Sector In China

China Healthcare

MW

McDermott Will & Emery

Landmark Whistleblower Program For China's Healthcare Sector

China Healthcare

AP

Arnold & Porter

Landmark Whistleblower Program For China's Healthcare Sector: Proposed Maximum Reward Of 1 Million RMB

China Healthcare

AP

Arnold & Porter

干细胞与基因治疗领域扩大开放新政及CAR-T地方监管新规初探

China Healthcare

AB

AnJie Broad Law Firm

China's NMPA Announces A Pilot Plan To Allow Non-End-To-End Manufacturing Of Biologics

China Healthcare

RG

Ropes & Gray LLP

无锡医保诈骗案相关问题与案例解析

China Insurance

AB

AnJie Broad Law Firm

医疗健康数据的法律保护与合规应用

China Healthcare

AB

AnJie Broad Law Firm

干细胞与基因治疗领域扩大开放新政及CAR-T地方监管新规初探

近年来细胞和基因治疗（CGT）领域随着相关科学理论、技术手段和临床医疗实践的不断演进而蓬勃发展。

China Healthcare

AB

AnJie Broad Law Firm

China's NMPA Announces A Pilot Plan To Allow Non-End-To-End Manufacturing Of Biologics

On October 21, 2024, the China National Medical Products Administration (NMPA) released a pilot plan that allows non-end-to-end manufacturing of biologics. The NMPA has a longstanding position to require an end-to-end...

China Healthcare

RG

Ropes & Gray LLP

无锡医保诈骗案相关问题与案例解析

2024年10月8日，国家医保局官方发布重磅消息，无锡某医院涉嫌违法违规使用医保基金2228.4万元，

China Insurance

AB

AnJie Broad Law Firm

医疗健康数据的法律保护与合规应用

数据资源作为重要生产要素蕴藏了巨大的价值，被认为是面向未来的数字经济"石油"，其中，医疗健康行业的数据公认具有较大的开发潜力。

China Healthcare

AB

AnJie Broad Law Firm

China's New Policies On Foreign Investment In Healthcare And Biotechnology: Catalyzing Innovation And Strengthening Patent Protection

L

Lusheng Law Firm

Mornington 2000 LLP (T/a Sterilab Services) & Anor V The Secretary Of State For Health And Social Care

The dispute here arose out of a contract for the supply of COVID-19 lateral flow test kits. In order to perform the contract, the second claimant ("Santé") had a subcontract with a German supplier ("Bio").

China Healthcare

FE

Fenwick Elliott LLP

"保险+互联网医疗"业态的合规要点

Q1、如果保险公司本身不具备或仅具备部分"互联网+医疗"相关经营资质，其可以如何合规地向其客户提供互联网医疗及/或药品销售服务？根据本ࢰ

China Insurance

AB

AnJie Broad Law Firm

"互联网+医疗"领域的主要业务类型及其关注热点（续）Q&A

如前期所述，互联网健康咨询的服务范围主要包括线上健康评估、健康指导、健康宣教、就诊指导、心理疏导等非诊疗行为的"信息服务业务"；&#

China Healthcare

AB

AnJie Broad Law Firm

Full Text: Joint Declaration Of The 9th ROK-Japan-China Trilateral Summit

The following is the full text of a joint declaration of the Ninth Trilateral Summit Meeting among China, Japan and the Republic of Korea (ROK) released on Monday.

China International

AC

AFD China

中国企业出海法律合规系列 ——欧盟首次启动《国际采购工具》对中国市场进行调查

China Commercial

AB

AnJie Broad Law Firm

"互联网+医疗"领域的主要业务类型及其关注热点

China Media & IT

AB

AnJie Broad Law Firm

China On The Move: Lessons From China's 2023 National Negotiation Of Drug Prices

China Healthcare

GT

Greenberg Traurig, LLP

一文透视《科技伦理审查办法（试行）》

ZL

Zhong Lun Law Firm

Patenting Medical Use Inventions In China

China Healthcare

CP

CCPIT Patent & Trademark Law Office

Redefining AI Research Ethical Boundaries? – FAQs On China's New Measures For Scientific Research And Innovations

China Technology

ZL

Zhong Lun Law Firm

Overview Of Recent Anti-Corruption Enforcement Actions In The Pharmaceutical Industry In China

SM

Sheppard Mullin Richter & Hampton

《RDPAC数字医疗合规指南》简析（公司内控合规系列）

China Healthcare

AB

AnJie Broad Law Firm

新时代医药反腐历程及重点罪名简析

China Healthcare

AB

AnJie Broad Law Firm

2023年度の国家医療機器政策

China Healthcare

NP

Nexdigm Private Limited

基因检测LDT模式的最新监管要点及合规建议——聚焦第53条及LDT试点方案生命科学与医疗健康系列

China Healthcare

AB

AnJie Broad Law Firm

创新医疗器械审批程序简介及知识产权相关问题探讨

CP

CCPIT Patent & Trademark Law Office

China Monthly Antitrust Update - April 2023

China Anti-trust

D

Dentons

Several Ways For Responding To Office Action Regarding Methods For Diagnosis And Treatment Of Diseases

K

Kangxin

Legal Health Check For Your Chinese Subsidiary In 2023

China Commercial

HC

Horizons Corporate Advisory Co Ltd

See more

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More